Departmental Affiliations
Contact Info
Research Interests
cost-effectiveness analysis, health economics, economic analysis alongside clinical trials, medical technology assessment, medical devices
Experiences & Accomplishments
Dr. de Lissovoy’s primary research interest is the application of cost-effectiveness analysis to the design and improvement of health care delivery systems. In this capacity he serves as Principal Economist for the Major Extremity Trauma Research Consortium (METRC), a network of approximately 30 clinical centers that has received funding from the Department of Defense to conduct multi-center clinical and economic studies relevant to the treatment and outcomes of orthopedic trauma sustained in the military.
Honors & Awards
Deputy Editor, Medical Care
Select Publications
Naci H, de Lissovoy G, Hollenbeak C, Custer B, Hofmann A, McClellan W, Gitlin M. Historical Clinical and Economic Consequences of Anemia Management in Patients with End-Stage Renal Disease on Dialysis Using Erythropoietin Stimulating Agents versus Routine Blood Transfusions: A Retrospective Cost-Effectiveness Analysis. J Med Econ 2012;15:293-304.
Cragin L, Pan F, Peng S, Zenilman JM, Green J, Doucet C, Chalfin D, de Lissovoy G. Cost-effectiveness of a Fourth-Generation Combination Immunoassay for Human Immunodeficiency Virus (HIV) Antibody and p24 Antigen for the Detection of HIV Infections in the United States. HIV Clin Trials. 2012;13:11-22
Turco MA, Cannon LA, Amorosi LS, Stern S, Stivland T, Underwood P, de Lissovoy G; Kansal A. Economic Modeling of Cost-Effectiveness for New Stent Platform Designs: TAXUS Element (ION) Stent Compared to Bare Metal Express Stent in Small Vessels. J Am Coll Cardiol. 2011;57(14s1):E1185-E1185.
de Lissovoy G, Fraeman K, Teerlink JR, Mullahy J, Salon J, Sterz R, Durtschi A, Padley RJ. Hospital costs for treatment of acute heart failure: Economic analysis of the REVIVE II Study. Eur J Health Econ. 2010:11:185-193
de Lissovoy G, Hutchins V, Murphy D, Song D, Fraeman K, Vaughn B. Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am J Infect Control. 2009:37:387-97.